Sonnet Biotherapeutics Holdings, INC 8-K filings

Sonnet BioTherapeutics Holdings, Inc. has released a corporate presentation in conjunction with their participation in the Virtual Investor Closing Bell Series on September 9, 2024.

Sonnet BioTherapeutics has been granted an extension until October 15, 2024, to regain compliance with Nasdaq's minimum bid price requirement through a reverse stock split.

Sonnet BioTherapeutics has partnered with the Sarcoma Oncology Center to advance the development of SON-1210, a novel immunotherapy, for metastatic pancreatic cancer.

Sonnet BioTherapeutics announced positive clinical trial updates for its lead program, SON-1010, and provided a corporate update including a new patent and financial results.

Sonnet BioTherapeutics received a delisting notice from Nasdaq due to non-compliance with the minimum bid price requirement, and the company plans to request a hearing to appeal the decision.

Sonnet BioTherapeutics reported encouraging Phase 1b clinical trial data for SON-080 in Chemotherapy-Induced Peripheral Neuropathy, supporting advancement to a Phase 2 study in Diabetic Peripheral Neuropathy.

Sonnet BioTherapeutics has entered into an agreement for the immediate exercise of existing warrants, generating $3.4 million in gross proceeds and issuing new warrants.

Sonnet BioTherapeutics Holdings, Inc. has filed a presentation with the SEC on June 13, 2024, as part of a current report.

Sonnet BioTherapeutics announces the development of two new immunotherapeutic drug candidates, SON-1411 and SON-1400, featuring a modified IL-18 domain designed to enhance anti-tumor activity.

Sonnet BioTherapeutics has initiated a review of strategic options, including potential partnerships, mergers, or acquisitions, to enhance shareholder value.

Sonnet BioTherapeutics reports updated clinical data for SON-1010, showing promising safety and efficacy signals, leading to an increase in the target dose for ongoing trials.

Sonnet BioTherapeutics Holdings, Inc. released a corporate presentation on May 14, 2024, providing an update on the company's activities.

Sonnet BioTherapeutics announced its financial results for the second quarter of fiscal year 2024, highlighting progress in clinical trials and cost-saving measures.

Sonnet BioTherapeutics has entered into an agreement with Chardan Capital Markets for a committed equity facility of up to $25 million.

Sonnet BioTherapeutics announced that its Phase 1b/2a clinical trial of SON-080 for chemotherapy-induced peripheral neuropathy has been cleared to proceed to Phase 2 after a positive safety review.

Sonnet BioTherapeutics Holdings, Inc. has successfully sold its New Jersey state net operating losses, receiving $4.3 million in net proceeds.

Sonnet BioTherapeutics announced its first quarter fiscal year 2024 results, highlighting progress in clinical trials and securing additional funding through a public offering and the sale of net operating losses.

Sonnet BioTherapeutics has regained compliance with Nasdaq's minimum stockholders' equity requirement after a recent sale of net operating losses.

Sonnet BioTherapeutics has sold its New Jersey net operating losses for $4.3 million and believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement.